CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BioDiem Ltd. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BioDiem Ltd.
Suite 3, Level 11, 470 Collins Street
Phone: +61 396134100p:+61 396134100 Melbourne, VIC  3000  Australia Fax: +61 396134111f:+61 396134111

This company is no longer actively traded on any major stock exchange.

Business Summary
BioDiem Limited is an Australia-based pharmaceutical development company. The Company is engaged in the development and commercialization of pharmaceutical and biomedical research. BioDiem’s primary project is the Live Attenuated Influenza Vaccine (LAIV) technology from the Institute of Experimental Medicine in St. Petersburg, Russia. Its products include BDM-I, which can be used as an antimicrobial for use in humans; LAIV-Vector, which can be used as platform for vaccine design, and BDM-E, which can be used as an agent that slows down the cell ageing process and prolongs cell life. On December 14, 2011 the Company acquired control of Savine Therapeutics Pty Ltd a company that has developed a method for designing synthetic vaccines that are expected to stimulate and enhance the body’s immune system.
(Source: ARS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/20136/30/2013Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Independent Non-Executive Chairman of the Board Hugh M.Morgan 6/30/2009 8/25/2005
Chief Executive Officer, Executive Director JuliePhillips 5/7/2010 7/14/2009
Chief Financial Officer Richard A.Wadley 11/15/2012 7/1/2002
4 additional Officers and Directors records available in full report.

Business Names
Business Name
BioDiem Limited
Savine Therapeutics Pty Ltd

General Information
Number of Employees: 5 (As of 6/30/2005)
Outstanding Shares: 142,105,934 (As of 6/30/2013)
Shareholders: 910
Stock Exchange: ASX
Fax Number: +61 396134111


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023